Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
批准号:
10322105
负责人:
KATHARINE C HSU
金额:
$60.84万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-01-05 至 2024-12-31
关键词:
Acute Myelocytic LeukemiaAffectAlgorithmsAllelesAllogenicAllograftingAntitumor ResponseBehaviorBindingBiological ModelsBone Marrow TransplantationCancer EtiologyCause of DeathCell Surface ReceptorsCellsClinicalClinical ResearchDataData ScientistDonor SelectionEducationFailureGene CombinationsGeneticGenetic PolymorphismGenotypeHLA-B AntigensImmuneImmune systemImmunogeneticsImmunologistIn VitroIncidenceIndividualInfluentialsLigandsMachine LearningMalignant NeoplasmsMediatingModelingNK cell receptor NKB1Natural Killer CellsOutcomePatientsPeptide Leader SequencesPeptidesPhenotypePhysiciansPlayPopulationPositioning AttributeProcessReceptor GeneRecurrent diseaseRelapseReproducibilityResearchRetrospective StudiesRiskRoleScientistShapesStatistical ModelsT cell responseT-LymphocyteTimeTissuesTrainingTransplant RecipientsTransplantationUnited StatesValidationVariantWorkadaptive immune responsebasecancer cellcohortcurative treatmentsdimorphismdisorder riskgraft vs host diseasegraft vs leukemia effecthematopoietic cell transplantationimmune functionin vivoleukemialeukemia relapsemachine learning modelmortalitynovel strategiespeptide Bpersonalized medicinepreventreceptorrelapse predictionresponse
中文摘要
摘要
异基因造血细胞移植(Hct)是治疗大多数急性白血病的唯一治疗方法。
髓系白血病(AML),但其50%的失败率仍然高得令人无法接受,主要是
疾病复发和移植物抗宿主病引起的死亡原因。当成功时,HCT防止
T细胞和自然杀伤(NK)细胞共同介导的移植物抗白血病效应引起的白血病复发
免疫功能。异基因移植能产生较高NK抗白血病反应的供者的选择
潜在但低GVHD风险仍然是HCT的主要未得到满足的需求。
多基因、多态的KIR受体与其人类白细胞抗原配体结合,控制NK
功能,规定NK谱系内容,并建立过程中NK细胞反应的阈值
被称为“NK教育”。HCT中的大型回顾性研究表明,特异性KIR-HL A
与NK教育相关的等位基因组合对复发控制有预测作用,但它们代表
只有一小部分已知的KIR-HLA相互作用。此外,在存在的数千种表型中,
在NK库中,负责HCT白血病控制的NK人群(S)尚不清楚,他们
移植对之间可能存在差异。目标1提出了一种集成自然语言的机器学习方法
基因,表型和功能,以确定基因如何决定整体曲目的反应和
哪些亚群对全球响应做出了最大贡献。NK基因分型的并行统计建模
在2800名AML患者的队列中,Hct结果可能证实了相同的基因型别
全球反应也在HCT结果中发挥作用,但也可能确定意想不到的结果。
人类白细胞抗原是移植物抗宿主病风险最重要的决定因素。精确的人类白细胞抗原配型降低了罹患
GVHD,但对于缺乏人类白细胞抗原相合供者的患者来说,预测允许的人类白细胞抗原不匹配是一个
派拉蒙和未得到满足的需求。根据M和T先导肽,存在两种人类白细胞抗原-B同种异型
人类白细胞抗原不相合的红细胞移植中的二型性和移植物抗宿主病风险因领导者的配型状态而异。
将人类白细胞抗原-B基因分成两个谱系,为功能基序的定位提供了一种新的途径
在移植中,这种移除减少了以前多态位置的绝对数量
排除了一次检查1个以上残留物的可能性。使用HLA数据的机器学习方法
来自11,000多名移植患者的数据将允许对血统变异的全谱进行评估
T细胞与NK同种异体反应的关系。
英文摘要
ABSTRACT
Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for most forms of acute
myelogenous leukemia (AML), but its 50% failure rate remains unacceptably high, with the principal
causes of death due to disease relapse and graft-versus-host disease. When successful, HCT prevents
leukemic relapse due to a graft versus leukemia effect, co-mediated by T cell and natural killer (NK) cell
immune functions. Selection of donors whose allografts will provide higher NK anti-leukemic response
potential but low GVHD risk remains a major unmet need in HCT.
The polygenic, polymorphic KIR receptors, in combination with their HLA ligands, control NK
function, dictating NK repertoire content and establishing thresholds for NK cell response in a process
called “NK education”. Large retrospective studies in HCT have demonstrated that specific KIR-HLA
allele combinations associated with NK education are predictive for relapse control, but they represent
only a fraction of known KIR-HLA interactions. Furthermore, out of the thousands of phenotypes present
in the NK repertoire, the NK population(s) responsible for leukemia control in HCT is unknown and they
likely differ between transplant pairs. Aim 1 proposes a machine learning approach to integrate NK
genotype, phenotype, and function to identify how genotype determines overall repertoire response and
which subpopulations contribute most to global response. Parallel statistical modeling of NK genotypes
and HCT outcome in a cohort of 2800 AML patient may confirm the same genotypes that are potent for
global response also play a role in HCT outcomes but may also identify unexpected ones.
HLA is the most important determinant of GVHD risk. Precise HLA matching lowers the risk for
GVHD, but for patients who lack HLA-compatible donors, predicting permissible HLA mismatches is a
paramount and unmet need. Two lineages of HLA-B allotypes exist based on the M and T leader peptide
dimorphism, and GVHD risk in HLA-mismatched HCT differs depending on the match status of the leader.
The division of the HLA-B locus into two lineages provides a novel approach for mapping functional motifs
in transplantation that removes reduces the sheer numbers of polymorphic positions that previously
precluded examination of more than 1 residue at a time. Machine learning approaches using HLA data
from more than 11,000 transplant patients will permit assessment of the full spectrum of lineage variation
and the relationship between T-cell and NK alloresponses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10390447
-
项目类别:
-
资助金额:$70.98万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
-
批准号:10590647
-
项目类别:
-
资助金额:$73.31万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
-
批准号:10534187
-
项目类别:
-
资助金额:$59.59万
-
财政年份:2021
-
负责人:KATHARINE C HSU
-
依托单位:
Natural killer cell and T-cell crosstalk in CMV infection
-
批准号:9398188
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2017
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9160652
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
KIR and HLA in cis and trans cooperatively shape human NK education
-
批准号:9310137
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma
-
批准号:9488351
-
项目类别:
-
资助金额:$24.99万
-
财政年份:2016
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:9271228
-
项目类别:
-
资助金额:$57.34万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
-
批准号:8865414
-
项目类别:
-
资助金额:$42.1万
-
财政年份:2015
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8508896
-
项目类别:
-
资助金额:$34.4万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8217684
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8544192
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
-
批准号:8730476
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8731836
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
-
批准号:8373670
-
项目类别:
-
资助金额:$36.44万
-
财政年份:2012
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7743072
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:8197289
-
项目类别:
-
资助金额:$41.65万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7383207
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Tolerance and Hematopoietic Cell Transplantation
-
批准号:7536389
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2007
-
负责人:KATHARINE C HSU
-
依托单位:
NK Receptors and Bone Marrow Transplant Outcome
-
批准号:6704624
-
项目类别:
-
资助金额:$12.91万
-
财政年份:2004
-
负责人:KATHARINE C HSU
-
依托单位:
海外基金